These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27683152)

  • 1. Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report.
    Arginelli F; Rongioletti F; Girolomoni G; Pellacani G; Guardoli D; Conti A
    J Int Med Res; 2016 Sep; 44(1 suppl):109-112. PubMed ID: 27683152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
    Sillard L; Passeron T; Cardot-Leccia N; Perrin C; Lacour JP; Ortonne JP
    Ann Dermatol Venereol; 2010 Jan; 137(1):48-52. PubMed ID: 20110069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system.
    Guarneri A; Cioni M; Rongioletti F
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1157-1160. PubMed ID: 28370513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
    Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
    Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin.
    Kulczycki A; Nelson M; Eisen A; Heffernan M
    Br J Dermatol; 2003 Dec; 149(6):1276-81. PubMed ID: 14674909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scleromyxoedema in a dog.
    Laprais AF; Bizikova P; Lashnits EW; Tucker A; Linder KE
    Vet Dermatol; 2017 Oct; 28(5):503-e119. PubMed ID: 28439995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleromyxoedema with disseminated subcutaneous nodules: rare presentation of an uncommon dermatosis.
    Singh S; Kanwar AJ; Saikia UN
    Clin Exp Dermatol; 2013 Jan; 38(1):36-9. PubMed ID: 22607617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does dermatoneuro syndrome have a viral aetiology?
    Bhoyrul B; Mughal AA; Paulus J; Salamat A; Howarth S
    Clin Exp Dermatol; 2016 Jan; 41(1):53-6. PubMed ID: 26175017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study.
    Nacci F; Righi A; Conforti ML; Miniati I; Fiori G; Martinovic D; Melchiorre D; Sapir T; Blank M; Shoenfeld Y; Pignone AM; Cerinic MM
    Ann Rheum Dis; 2007 Jul; 66(7):977-9. PubMed ID: 17344244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of scleromyxoedema following treatment with extracorporeal photopheresis.
    Krasagakis K; Zouboulis CC; Owsianowski M; Ramaker J; Trautmann C; Tebbe B; Orfanos CE
    Br J Dermatol; 1996 Sep; 135(3):463-6. PubMed ID: 8949446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of scleromyxoedema with hydroxychloroquine.
    Terheyden P; Becker JC; Lurz C; Kahaly GJ; Bröcker EB
    J Dtsch Dermatol Ges; 2003 Jan; 1(1):30-5. PubMed ID: 16285290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
    Topf S; Simon M; Schell H; Lüftl M
    Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Gammopathy of Undetermined Significance-associated Scleromyxoedema.
    Baxi KD; Chaudhary RG; Rathod SP; Jagati A
    Indian Dermatol Online J; 2019; 10(1):54-57. PubMed ID: 30775300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
    Le Moigne M; Mazereeuw-Hautier J; Bonnetblanc JM; Astudillo L; D'Incan M; Bessis D; Thomas L; Debarbieux S; Ammoury A; Lamant L; Paul C
    Ann Dermatol Venereol; 2010 Dec; 137(12):782-8. PubMed ID: 21134580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin.
    Shergill B; Orteu CH; McBride SR; Rustin MH
    Br J Dermatol; 2005 Sep; 153(3):650-2. PubMed ID: 16120159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulins control scleromyxoedema.
    Righi A; Schiavon F; Jablonska S; Doria A; Blasczyk M; Rondinone R; Todesco S; Matucci Cerinic M
    Ann Rheum Dis; 2002 Jan; 61(1):59-61. PubMed ID: 11779761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.
    Danieli MG; Cappelli M; Malcangi G; Logullo F; Salvi A; Danieli G
    Ann Rheum Dis; 2004 Dec; 63(12):1649-54. PubMed ID: 15547090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atypical papular mucinosis with initial histological findings evocative of granuloma annulare].
    de Cambourg G; Joganah N; Cribier B
    Ann Dermatol Venereol; 2012 Jan; 139(1):58-62. PubMed ID: 22225745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide.
    Peter LM; Ammoury A; Chiavassa-Gandois H; Lamant L; Paul CF
    Clin Exp Dermatol; 2008 Aug; 33(5):606-10. PubMed ID: 18477005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
    Laimer M; Namberger K; Massone C; Koller J; Emberger M; Pleyer L; Hintner H; Greil R
    Acta Derm Venereol; 2009 Nov; 89(6):631-5. PubMed ID: 19997697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.